Updated:
Tellus BioVentures
Tellus BioVentures is a life sciences investment fund focused on early-stage innovation and company formation. Tellus was founded in 2019 to uncover and...
Tellus BioVentures
Tellus BioVentures is a life sciences investment fund focused on early-stage innovation and company formation. Tellus was founded in 2019 to uncover and accelerate promising life science innovation, enable talented entrepreneurs and scientists, and serve patients with unmet needs. For more information, please visit www.tellusbv.com.
General information
Firm type
Venture Capital
Year founded
2019
Location
Region
North America
Country
United States
City
Florida
Corporate office
Florida, United States
Sector focus
Frequently asked questions
What investment stage does Tellus BioVentures target?
Tellus BioVentures targets seed-stage life-science companies, entering at formation or first institutional round. Public records indicate the firm focuses on ventures that are pre-revenue but have reached proof-of-concept in a relevant validation layer — in silico, in vitro, or in an animal model. The firm's posture is to underwrite specific therapeutic or diagnostic theses at inception rather than index the broader sector.
Which sectors does Tellus BioVentures explicitly target?
Tellus BioVentures targets therapeutics, diagnostics, and care-delivery platforms at the intersection of deep science and computation. Its sector coverage includes biotech, medical devices, and health-AI — specifically machine-learning applications for drug discovery, clinical-trial optimization, and precision-medicine workflows. The firm positions itself where biological breakthroughs meet unmet medical need.
Where does Tellus BioVentures source its deal flow?
Tellus BioVentures is headquartered in Florida, which positions it to source from founders emerging from the southeastern United States' growing academic-medical corridors — institutions such as the University of Florida, University of Miami, and the Moffitt Cancer Center ecosystem. The firm maintains connectivity to coastal venture hubs while exploiting a geographic advantage in a region that is often less competitively shopped by Boston- and San Francisco-based biotech seed funds.
Profile maintained by Altss using OSINT (open-source intelligence), regulatory filings, licensed data partners, and verified direct submissions. Read the methodology. Last updated: . Continuous refresh with full update cycles at least every 30 days.
Need institutional-grade insight on venture capital firms?
Altss delivers:
Prefer a guided tour?
We’ll walk you through: